Table 22-13.

Quality of Care by Race/Ethnicity and Sex in the GWTG-HF Program, 2012

Quality-of-Care Measure	White	Black	Hispanic	Men	Women
Postdischarge appointment (new for 2011)*	48.4	53.6	41.7	49.9	48.4
Complete set of discharge instructions†	93.2	94.3	93.2	93.9	92.9
Measure of LV function*	96.4	96.4	92.7	96.8	95.9
ACEI or ARB at discharge for patients with LVSD, no contraindications*	95.0	96.5	95.3	95.5	95.3
Smoking cessation counseling, current smokers†	97.1	97.9	95.9	97.3	97.1
Evidence-based specific β-blockers*	82.0	86.4	84.2	83.9	82.8
β-Blockers at discharge for patients with LVSD, no contraindications†	97.4	97.6	96.2	97.3	97.3
Hydralazine/nitrates at discharge for patients with LVSD, no contraindications‡	…	20.1	…	21.3	17.0
Anticoagulation for AF or atrial flutter, no contraindications	79.8	76.0	69.2	80.6	76.7
Composite quality-of-care measure (with discharge instructions and β-blocker at discharge)	93.3	93.8	89.9	93.9	92.9

Values are percentages.

Quality-of-care measures stratified by race/ethnicity and sex are reported for hospitals participating in GWTG from January 1, 2012, through December 31, 2012.

ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; ellipses (…), no data; GWTG-HF, Get With The Guidelines–Heart Failure; LV, left ventricular; and LVSD, left ventricular systolic dysfunction.

^*Indicates the 4 key achievement measures targeted in GWTG-HF.

^†Indicates historical key achievement measures in GWTG-HF.

^‡For black patients only.